SOURCE: Curidium Medica PLC

May 14, 2007 02:03 ET

Curidium Develops Blood Diagnostic Test For Schizophrenia/Bipolar Disorder Patient Subgroups

London -- (MARKET WIRE) -- May 14, 2007 --

               Curidium Medica plc ("Curidium" or the "Company")

CURIDIUM DEVELOPS BLOOD DIAGNOSTIC TEST FOR SCHIZOPHRENIA/BIPOLAR DISORDER
                               PATIENT SUBGROUPS

  - Major Advance towards More Effective and Safer Drug Treatments   -
London, UK, 14 May 2007, Curidium Medica Plc, (LSE: CUR), the personalized medicine company focused on bringing the right drug to the right patient, today announced it has developed a blood diagnostic test that can sub-classify patients with schizophrenia/bipolar disorder into one of four subgroups. This is the first time that a schizophrenia/bipolar disorder diagnostic blood test has been developed that classifies patients into different subgroups that are each associated with distinct underlying disease mechanisms and specific drug targets. The discovery, using Curidium's proprietary technology Homomatrix®, of highly statistically significantly different schizophrenic/bipolar disease patient subgroups was announced previously by the Company.

Curidium's diagnostic test is based on the levels of expression of 28 genes in blood samples of schizophrenia/bipolar disorder patients. The test was designed using the Homomatrix® technology and gene expression data was applied from blood samples of 115 patient and control donors. The test was subsequently assessed using blood samples from a different group of 32 schizophrenia/bipolar disorder patients in order to determine the test's specificity and sensitivity. The overall specificity or ability of the test to avoid incorrectly selecting a patient for a subgroup was ninety-four percent (94%). The overall sensitivity, which determines the ability of the test to detect the subjects belonging to a subgroup, was seventy-eight percent (78%).

The Company believes its diagnostic test could potentially lead to the more accurate prescription of marketed products as well as enable the identification and development of better and/or new subgroup specific drug treatments. The test will potentially benefit 1) patients, providing safer and more effective treatments, 2) the pharmaceutical industry, allowing more time and cost effective development of new drugs and 3) healthcare payers, such that the prescription of ineffective treatments may be avoided. Generally, only a minority of schizophrenia/bipolar disorder patients respond to a drug treatment.

"The development of a blood test improving the accuracy of diagnosis and potential treatment of schizophrenia/bipolar disorder patients represents a significant advance in the treatment of these diseases," stated Dr. Anne Bruinvels, CEO of Curidium Medica plc. "This particular test and the application of Homomatrix to psychiatric and other disorders has the potential to support the development of much needed, effective and safe drugs for difficult-to-treat patients."

For further information please contact:

Anne Bruinvels +44 (0) 20 7554 8790

CEO, Curidium Medica plc

Rob Smith +44 (0) 20 7554 8793

Finance Director, Curidium Medica plc

Rhodri Cruwys / Romil Patel +44 (0) 20 7448 4400

Blue Oar Securities Plc

Billy Clegg / Edward Westropp / Anna Keeble + 44 (0)20 7831 3113

Financial Dynamics

Notes to Editors

Homomatrix®

Homomatrix® is a fully automated analysis tool that uses proprietary pattern recognition tools and sequences of mathematical algorithms together with state-of-the-art statistical methods to objectively analyze large sets of gene expression and biological data from heterogeneous populations. These analyses can potentially lead to the development of diagnostics that identify treatment-responsive patients and/or patient subgroups, signalling pathways as well as drug targets. It is anticipated that Homomatrix® could be of significant value in the drug development arena where the "most likely to respond" patients could be pre-selected to clinical trials.

Schizophrenia/Bipolar Disorder

Schizophrenia is a psychotic disorder characterized in the active phase by hallucinations, delusions, disorganized thoughts/speech, disorganized or catatonic behavior, and apathy. It is estimated that 1% of the general population suffer from schizophrenia.

Bipolar affective disorder, also known as manic-depressive illness, is a mental illness involving episodes of serious mania and depression. The person's mood usually swings from overly "high" and irritable to sad and hopeless, and then back again, with periods of normal mood in between. It is estimated that 0.5% of the general population suffer from bipolar affective disorder.

The global market for antipsychotics, which are used to treat schizophrenia and frequently bipolar affective disorder was valued at $12.5 billion in 2004 and is expected to grow to $20.5 billion by 2009 (The CNS Market Outlook to 2010, Reuters Business Insights, 2005).

Further information about schizophrenia and bipolar affective disorder can be found at www.schizophrenia.com or www.moodswing.org.

Curidium Medica

Curidium), the personalized medicine company focused on bringing the right drug to the right patient, is focused on identifying targeted medicines to treat patients more effectively. Through the application of its proprietary technology, Homomatrix®, Curidium analyses biological data (gene expression/ protein data) from patients suffering from complex or multi-factorial diseases. Patient populations with complex disorders are known to be heterogeneous and only certain subgroups of patients respond to a specific treatment. Curidium believes that Homomatrix will ultimately allow for the development of the right drug for the right patient. The Company files patents around the genes and drug targets that are associated with the specific subgroups of patients. Further information on Curidium can be found at the Company's website: www.curidium.com.

Curidium Medica plc (c) 2002-2007. All rights reserved. Hamilton House, Mabledon Place, London WC1H 9BB, United Kingdom. Email: info@curidium.com Tel.: +44 (0)20 7554 8790, Fax: +44 (0)20 7554 8791

                      This information is provided by RNS
            The company news service from the London Stock Exchange